MAR 10, 2015 09:00 AM PDT
Newly Updated Guidelines for the Diagnosis of Multiple Myeloma
SPONSORED BY: Binding Site
17 53 16876

  • Chief of Myeloma Service, Memorial Sloan Kettering Cancer Center
      Dr. Ola Landgren gained his MD in 1995 from Karolinska Institute, Stockholm, Sweden. Currently, Dr. Landgren is Chief of Myeloma Service at Memorial Sloan-Kettering Cancer Center in New York, NY. He holds a PhD in Diagnostics and Prognostics in Lymphoid Malignancies from Karolinska Institute, Stockholm, Sweden. He has published over 300 papers including a definitive prospective cancer screening study showing that myeloma is consistently preceded by a precursor state. Since 2007, Dr Landgren's translational research has particularly focused on the development of early treatment in smoldering myeloma and newly diagnosed multiple myeloma, paired with cell-based and molecular-based minimal residual disease (MRD) monitoring.

    DATE: Tuesday, March 10, 2015
    TIME: 09:00 PST, 11:00 CST, 12:00 EST, 16:00 GMT

    The International Myeloma Working Group (IMWG) has issued updated criteria for the diagnosis of multiple myeloma.

    The updated criteria, published in The Lancet Oncology represent a significant change in how Multiple Myeloma is diagnosed and the stage at which patients should be treated.

    Join us on March 10th on a webinar covering these updated criteria for Myeloma and related plasma cell disorders and the importance of biomarkers in Early Stage Disease.
    Following this presentation the listener will:
    • Understand the history and traditional tools used to diagnose Myeloma
    • Gain an appreciation for the evolution of Myeloma diagnosis and biomarkers of the disease
    • Be able to understand how to apply the new diagnostic guidelines to the diagnosis and treatment of Myeloma.

    Show Resources
    Loading Comments...